The true cost of cancer treatment in Singapore is bigger than the chemo bill, and most people only find out after a diagnosis. Late-stage treatment commonly runs S$8,000 to S$17,000 a month, and a full year of immunotherapy can hit S$156,000 to S$234,000. Since cancer drug coverage was tightened in 2022, MediShield Life and your Integrated Shield Plan no longer pay 'as charged' for cancer drugs. MediShield Life pays a fixed monthly limit per approved drug (S$200 to S$12,800 a month under the limits from 1 June 2026), your Shield plan tops that up to roughly 5 times that limit if the drug is on the Cancer Drug List, and anything off the list is on you. Below are the 2026 prices broken down by treatment type, where the real gap sits once the limits run out, and the MediSave, subsidy and charity routes that cushion it. The single biggest move is having the right insurance in place before any diagnosis, because you cannot buy cover for a cancer you already have.
There is no single price for cancer because the bill depends on the type, the stage, and how aggressively you treat it. A small early tumour caught at screening and removed in a day surgery might cost a few thousand dollars. A late-stage cancer needing surgery, radiotherapy, then months of immunotherapy can pass S$200,000 across a year and a half. Clinicians put monthly late-stage treatment in the S$8,000 to S$17,000 band, before you add scans, blood tests, consultations and the drugs that manage side effects.
Where you treat matters as much as what. A subsidised Singapore Citizen in a public hospital (Class B2 or C, or subsidised outpatient at NCCS or NUH) pays a fraction of the private rate, because the government subsidy and post-subsidy MediShield Life limits are built around those bills. A private hospital or private oncologist charges the full sticker price, and that is where five and six-figure annual bills come from. The treatment can be clinically identical; the price tag is not.
The figures below are typical 2026 ranges from Singapore oncology providers. Treat each as a starting point, not a quote, since dosing is weight-based and the regimen varies by patient. The point is the order of magnitude: cancer is not a S$5,000 problem, it is a S$50,000 to S$200,000 problem if it goes late or private.
| Treatment | Typical 2026 cost | Notes |
|---|---|---|
| Chemotherapy | ~S$1,500 per cycle; some regimens S$1,300 to S$3,300+ | Multiple cycles over months; cost depends on drug and dose |
| Radiotherapy | ~S$25,000 to S$30,000 for a full course | Stereotactic and proton therapy cost more |
| Surgery (private hospital) | ~S$18,500 to S$32,700 | Public, subsidised bills are far lower |
| Immunotherapy | ~S$9,000 per dose; S$156,000 to S$234,000 a year | Dose every 2 to 3 weeks; among the priciest options |
| Targeted therapy | Thousands to tens of thousands per month | Depends on the specific drug; many are on the Cancer Drug List |
| Late-stage, all-in | S$8,000 to S$17,000 per month | Combination of surgery, drugs, radiotherapy and supportive care |
Cancer is not a rare event you can gamble on avoiding. The Singapore Cancer Registry recorded an average of 50 people diagnosed and 17 people dying from cancer every day across 2019 to 2023, and 1 in 4 residents is expected to develop cancer by age 75. Those odds are why every working adult should treat the cost question as a when, not an if.
The cancers you are most likely to face are also the expensive ones to treat. In men, prostate (18.0% of cases), colorectal (15.8%) and lung (13.2%) lead. In women, breast dominates at 29.9%, then colorectal (12.6%) and lung (8.1%). Breast, lung and colorectal all routinely run long drug regimens, which is exactly where the insurance limits bite hardest.
Here is the part most cost articles skip: better survival makes the bill bigger, not smaller. The five-year survival rate across all cancers in Singapore has climbed from under 20% in the 1970s to 61.4% for 2019 to 2023. Surviving longer means more years of scans, maintenance drugs and follow-up, so the modern financial risk is less a single catastrophic bill and more a sustained drain over months or years. Planning for cancer is planning for a long, expensive condition you are increasingly likely to live through.
Two choices move your bill more than anything else: where you treat, and how early it is caught. A subsidised Singapore Citizen in a public hospital pays a means-tested fraction of the private rate for the same clinical procedure, because government subsidy is applied before MediShield Life even starts paying. The gap is not small. National University Cancer Institute Singapore publishes bill benchmarks (accurate as at 1 January 2024) showing a breast cancer day surgery at roughly S$514 subsidised versus S$1,373 unsubsidised at the same hospital, before you reach the much larger gap on a full private-hospital admission.
Stage at diagnosis is the other lever. A tumour caught early at screening and removed in a day procedure can be a four-figure event. The same cancer found late, needing surgery, radiotherapy and then months of drugs, is the S$8,000 to S$17,000 a month scenario. This is why screening is a financial decision as much as a medical one: a colonoscopy or mammogram that catches disease early can save both your life and a six-figure bill. MediSave and subsidies cover several recommended screenings.
The table below shows the shape of the gap rather than a quote for your case. Use it to grasp the order of magnitude: the same treatment can cost three to ten times more in a private setting, and a late-stage course costs many times an early-stage one. Run the cost-sharing against your own savings with our financial health check.
| Scenario | Typical range | What drives it |
|---|---|---|
| Subsidised day surgery (public) | Hundreds to low thousands | Means-tested subsidy applied before MediShield Life; e.g. breast day surgery ~S$514 subsidised at NCIS benchmarks |
| Unsubsidised day surgery (public, Class A) | Low thousands | No subsidy; e.g. breast day surgery ~S$1,373 unsubsidised at NCIS benchmarks |
| Private hospital surgery | ~S$18,500 to S$32,700 | Full sticker price; IP covers most, you pay deductible and co-insurance |
| Early-stage, caught at screening | A few thousand | Day surgery or short course; minimal drug load |
| Late-stage, all-in | S$8,000 to S$17,000 per month | Surgery plus radiotherapy plus months of drugs and supportive care |
Before 2022, cancer drugs were a money pit for the whole insurance system. Insurers paid for outpatient cancer drugs on an 'as charged' basis, which meant clinics had no reason to hold prices down and Singapore was paying far more than other developed countries for the same medicines. MediShield Life premiums and Integrated Shield Plan premiums were climbing fast as a result.
The Ministry of Health fixed this with the Cancer Drug List (CDL). From 1 September 2022, MediShield Life and MediSave only pay for outpatient cancer drug treatments that are on this published list, and each treatment has its own fixed claim limit instead of an open cheque. Integrated Shield Plans followed from 1 April 2023, capping their cancer drug payout at a multiple of the MediShield Life limit (commonly 5 times) for listed drugs, and dropping the old 'as charged' model.
About nine in ten cancer drug treatments are on the CDL, so for most patients the system still pays. The list is updated every four months, with the latest version dated 1 June 2026. The catch is the remaining one in ten: a drug that is not on the list, or a combination used in a way the list does not recognise, gets no MediShield Life, no MediSave and no standard Shield-plan payout for the drug itself. That is the single most important thing to understand before assuming you are covered.
MediShield Life is the national health insurance every Singapore Citizen and PR has by default, and the MediShield Life Council's review enhanced it in stages from 1 April 2025. It is sized around subsidised public-hospital (Class B2/C) bills, so it covers most of a subsidised patient's cost and only a slice of a private bill. You can read how the broader scheme works in our guide to insurance in Singapore, but here is what matters for cancer.
Under the enhanced scheme the annual claimable limit is S$200,000 (raised from S$150,000), with no lifetime cap. Daily ward coverage rose too: a normal ward is now S$1,630 a day for the first two days (was S$1,000) and ICU is S$5,140 a day (was S$2,200). Radiotherapy is claimable at S$400 per external treatment, S$460 per stereotactic treatment and S$620 per brachytherapy treatment. Surgery is covered by complexity table, from S$240 for the simplest up to S$3,900 for the most complex.
For cancer drugs specifically, outpatient cancer drug treatment on the CDL is claimable at S$200 to S$12,800 a month depending on the drug, and cancer drug services (the scans, blood tests, consultations and supportive drugs around the treatment) are claimable up to S$4,500 a year for a single primary cancer, or S$9,000 for multiple primary cancers. MediSave can also be tapped for CDL cancer drugs, up to S$600 a month for most drugs and up to S$1,200 a month where the MediShield Life claim limit for the drug is above S$5,400, if MediShield Life and any Shield plan do not fully cover the bill.
Two cost-sharing rules are worth budgeting for. From 1 June 2026 there is a new S$500 annual outpatient deductible (which you can pay from MediSave). Outpatient co-insurance moved to a tiered structure that is cheaper on big bills: 10% on the first S$5,000 of the claimable amount, 5% on the next S$5,000, and 3% above S$10,000. The inpatient deductible, raised in phases from 1 April 2025, sits at S$2,000 for Class C, S$2,500 for Class B2, and S$3,500 for Class A or private hospital (for those aged 80 and below), with a further phase scheduled for 1 April 2027.
An Integrated Shield Plan (IP) is the private add-on most working Singaporeans buy on top of MediShield Life to cover private hospitals or unsubsidised Class A wards. For inpatient cancer surgery, radiotherapy and hospital stays, a good IP pays the bill 'as charged' up to your plan's limit, so the financial exposure there is mostly your deductible and co-insurance, which a rider can reduce further. That part still works the way people expect.
Cancer drugs are the exception, and this is where many people are over-confident. Since 1 April 2023, an IP only pays for outpatient cancer drug treatment if the drug is on the CDL, and it pays a multiple of the MediShield Life limit rather than the full charge. The standard multiple is 5 times the MediShield Life limit for the drug, which works out to roughly S$1,000 to S$48,000 a month across the range. Some 2026 plans, with riders, stretch this to 15 times for certain tiers. The exact multiple and any extra cancer drug benefit depend on your specific plan and insurer, so check your policy schedule, not a general article.
Two gaps survive even with a top-tier IP. First, a drug that is not on the CDL is not covered at all by the standard IP cancer drug benefit, so a five-figure monthly drug could fall entirely on you. Second, even within the CDL, an expensive drug priced above 5 times the MediShield Life limit leaves a co-payment. This is why a few insurers sell a separate, optional cancer drug rider or a standalone cancer policy that pays beyond the CDL framework. If your treatment plan involves a newer or off-list drug, that extra layer is the difference between a manageable bill and a forced downgrade in treatment.
Take a Singapore Citizen on a private Integrated Shield Plan diagnosed with a cancer needing surgery, then a year of an immunotherapy drug that is on the CDL with a MediShield Life claim limit of S$5,000 a month.
The surgery and stay at a private hospital might bill S$30,000. The IP pays this as charged up to plan limits, so after the inpatient deductible (S$3,500 for private, paid once a policy year) and co-insurance (reduced if you hold a rider), the out-of-pocket on the surgery is a few thousand dollars at most. So far, manageable.
The drug is where it bites. At S$9,000 a dose every three weeks, the immunotherapy bills roughly S$12,000 a month. MediShield Life pays its S$5,000 monthly limit, and the IP adds 5 times that limit, so the combined cancer drug cover is around S$25,000 to S$30,000 a month, which clears a S$12,000 CDL drug with room to spare. Over a year that is the system working as designed, with you covering deductibles, co-insurance and supportive-care costs above the cancer drug services limit.
Now change one thing: the drug is not on the CDL. MediShield Life pays nothing, the standard IP cancer drug benefit pays nothing, and the S$12,000 a month is yours unless you bought a cancer drug rider or a standalone cancer plan covering off-list drugs. That is S$144,000 over a year. The gap is not in the surgery or the ward; it is almost always in the drugs. Run your own numbers with our budget calculator and see how long a buffer survives at S$12,000 a month.
Public-sector subsidies do the heavy lifting before any insurance. A subsidised Singapore Citizen at a restructured hospital or the National Cancer Centre gets means-tested government subsidies on consultations, scans, radiotherapy and CDL drugs, which is why subsidised bills are a fraction of private ones. If you hold a CHAS card, it lowers your costs at participating GPs and dentists, and the CHAS tier feeds into other assistance below. The trade-off is less choice of doctor and timing than the private route.
MediSave is your own forced-savings account and it is more flexible for cancer than most people realise. Beyond the S$600 a month for CDL cancer drugs, MediSave covers approved screening, day-surgery withdrawal limits, and the S$500 outpatient deductible. You can also use an immediate family member's MediSave, so a spouse's or adult child's account can help carry the cost. It does not cover non-CDL drugs, so it cannot plug the worst gap on its own.
Charity and hardship funds catch people who fall through. The Singapore Cancer Society's Cancer Care Fund gives a one-time grant within six months of diagnosis: S$500 for an Orange CHAS card holder and S$1,000 for a Blue CHAS or Public Assistance card holder, subject to means-testing. The National Cancer Centre Singapore runs its own NCCS Cancer Fund for needy patients, and MediFund is the government's safety net for citizens who still cannot pay after subsidies, MediShield Life and MediSave. These are real but modest against a six-figure drug bill, so they are a backstop, not a plan.
Even a fully insured patient bleeds money in ways the claim never shows. Insurance pays the medical bill; it does not pay for the life that grinds on around treatment. Budget for these from day one, because they are the costs that quietly empty a savings account while the big bills are technically covered.
The biggest of the hidden costs is lost income. Treatment can mean months of reduced hours or no work at all, and a caregiver, often a spouse, may cut back too. For a single-income household that is the real threat, not the deductible. This is the gap a lump-sum critical illness payout is designed to fill, since it lands as cash you can spend on rent and groceries, not just drugs.
Then there is the steady trickle: travel to daily radiotherapy or weekly infusions, parking, special nutrition and supplements, home help, wigs and prosthetics, and the follow-up scans and blood tests that continue for years after active treatment ends. Cancer drug services under MediShield Life cap at S$4,500 a year for a single cancer, so the surrounding costs above that limit are yours. None of these are large on their own, but across a year of treatment they routinely add up into the low tens of thousands, which is precisely why a cash buffer sits alongside insurance in the plan below.
You cannot buy insurance for a cancer you already have, so every decision here is one to make while you are healthy. The base layer is keeping an Integrated Shield Plan you can actually afford long-term, ideally with a rider that caps your annual out-of-pocket, so a private bill does not wipe out savings. If you are weighing whether to insure privately at all, our pages on Integrated Shield Plans and MediShield Life explain what each layer pays.
The specific cancer gap, the non-CDL drug, is best closed by either a cancer drug rider on your Shield plan or a standalone cancer policy. A standalone plan usually pays a lump sum on a defined cancer diagnosis, which you can spend on any treatment including off-list drugs, second opinions, or income replacement while you cannot work. A separate route is a critical illness policy, which pays out a lump sum on diagnosis of cancer (and other defined illnesses) regardless of the actual treatment cost, often via a early-stage CI rider that triggers sooner. Term life or a CI plan is the cheapest way to buy a large lump sum, and our guide to term life covers the basics.
Whatever cover you choose, build the cash layer behind it. Even fully insured patients pay deductibles, co-insurance, transport, supplements and lost income, and that easily runs into the low tens of thousands across a year of treatment. A standing emergency fund of six to twelve months of expenses absorbs the cost-sharing without forcing a panic sale of investments at the wrong time. The order that works is simple: MediShield Life by default, an IP with a rider on top, a lump-sum cancer or CI policy for the off-list gap, then cash savings to absorb everything insurance does not.
It depends heavily on stage and setting. Late-stage treatment commonly runs S$8,000 to S$17,000 a month, and a full year of immunotherapy can cost S$156,000 to S$234,000. Chemotherapy is around S$1,500 a cycle, a radiotherapy course S$25,000 to S$30,000, and private cancer surgery S$18,500 to S$32,700. Subsidised public-hospital bills for Singapore Citizens are far lower than private ones.
Yes, but with fixed limits. The annual claimable limit is S$200,000 (raised from S$150,000 under the MediShield Life Council review). Outpatient cancer drug treatment on the Cancer Drug List is claimable at S$200 to S$12,800 a month depending on the drug, with up to S$4,500 a year for cancer drug services (single primary cancer). Drugs not on the Cancer Drug List get no MediShield Life payout for the drug.
The Cancer Drug List (CDL) is the Ministry of Health's published list of outpatient cancer drug treatments that MediShield Life, MediSave and Integrated Shield Plans will pay for, each with its own claim limit. About 90% of cancer drug treatments are on it, and it is updated every four months (latest 1 June 2026). If your drug is not on the CDL, MediShield Life, MediSave and the standard Shield-plan cancer drug benefit pay nothing for it.
Only if the drug is on the Cancer Drug List. Since April 2023, IPs pay outpatient cancer drugs at a multiple of the MediShield Life limit, commonly 5 times (roughly S$1,000 to S$48,000 a month), and some plans with riders reach 15 times. A non-CDL drug gets no standard IP cancer drug payout, so you would need a separate cancer drug rider or a standalone cancer policy to cover it.
Yes, within limits. MediSave covers up to S$600 a month for most cancer drugs on the Cancer Drug List (up to S$1,200 a month for drugs with a MediShield Life claim limit above S$5,400), plus the S$500 annual outpatient deductible, day-surgery withdrawal limits, and approved screening. You can also use an immediate family member's MediSave. MediSave does not cover drugs that are off the Cancer Drug List.
Subsidised public-hospital and NCCS care comes with means-tested government subsidies. The Singapore Cancer Society's Cancer Care Fund gives a one-time S$500 (Orange CHAS) or S$1,000 (Blue CHAS / Public Assistance) within six months of diagnosis. The NCCS Cancer Fund helps needy patients, and MediFund is the government safety net for citizens who still cannot pay after subsidies, MediShield Life and MediSave.
No. Insurers will not cover a pre-existing cancer, and existing policies may exclude it. This is why the cover that matters, an Integrated Shield Plan with a rider plus a lump-sum cancer or critical illness policy, has to be in place while you are healthy. Once diagnosed, your options narrow to subsidies, MediSave, existing insurance and charity funds.
Very common. The Singapore Cancer Registry recorded an average of 50 people diagnosed and 17 dying from cancer every day across 2019 to 2023, and 1 in 4 residents is expected to develop cancer by age 75. The most common cancers are prostate, colorectal and lung in men, and breast, colorectal and lung in women. Because the five-year survival rate has risen to 61.4%, more people now live with cancer as a long-term, costly condition rather than a short crisis.
Yes, often dramatically, if you qualify as a subsidised patient. A subsidised Singapore Citizen at a public hospital pays a means-tested fraction of the private rate for the same procedure. As one example, National University Cancer Institute Singapore benchmarks a breast cancer day surgery at roughly S$514 subsidised versus S$1,373 unsubsidised, and the gap on a full private-hospital admission is far larger. The trade-off is less choice over your doctor and appointment timing than the private route.
Insurance pays the medical bill, not the life around it. The largest hidden cost is lost income for the patient and often a caregiver. On top of that come transport and parking for frequent treatment, nutrition and supplements, home help, wigs and prosthetics, and years of follow-up scans and blood tests. Cancer drug services under MediShield Life cap at S$4,500 a year for a single cancer, so surrounding costs above that are yours. A lump-sum critical illness payout and a cash buffer are what cover these.
Yes. Stage at diagnosis is one of the biggest cost drivers. A cancer caught early at screening and removed in a day procedure can be a four-figure event, while the same cancer found late can run S$8,000 to S$17,000 a month once it needs surgery, radiotherapy and months of drugs. MediSave and government subsidies cover several recommended screenings such as mammograms and colonoscopies, so screening is a financial decision as much as a medical one.
This is general financial information for Singapore, not personal financial advice. Figures change — verify current rates against the official sources above before acting. See our full disclaimer.